onc Videos

Videos

Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center

Videos

Global Treatment of Gastric/GEJ Cancer with Durvalumab Plus FLOT

01/19/2024

Yelena Janjigian, MD, discussed the recent subgroup analysis from the MATTERHORN study, evaluating durvalumab plus FLOT for patients with gastric or gastroesophageal junction cancer.

Yelena Janjigian, MD, discussed...

01/19/2024

Oncology

Joseph Mikhael, MD, City of Hope Cancer Center

Conference Coverage

Strategies for Treating Patients With Multiply Relapsed Multiple Myeloma

01/19/2024

Joseph Mikhael , MD, MEd, FRCPC;

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.

At the 2023 Lymphoma, Leukemia &...

01/19/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Benefits of MRD Testing for the Treatment of Patients With Multiple Myeloma

01/19/2024

Joseph Mikhael , MD, MEd, FRCPC;

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, participated in a debate on the benefits of minimal residual disease testing in multiple myeloma treatment.

At the 2023 Lymphoma, Leukemia &...

01/19/2024

Lymphoma, Leukemia & Myeloma Network

Videos

Examining Factors to Consider in the Treatment of Patients With Indolent B-Cell Lymphomas

01/15/2024

Gilles Salles , MD, PhD;

Gilles Salles, MD, PhD, offers advice for fellow oncologists in the B-cell lymphoma space, highlighting the need for strategically chosen therapies to minimize the risk of transformations.

Gilles Salles, MD, PhD, offers...

01/15/2024

Oncology

Conference Coverage

Subcutaneous Mosunetuzumab Demonstrates Encouraging Efficacy, Manageable Safety as Frontline Therapy for High-Tumor Burden Follicular Lymphoma

01/12/2024

Lorenzo Falchi ;

At the 65th ASH Annual Meeting, Lorenzo Falchi, MD, shares results which indicated that subcutaneous mosunetuzumab as first-line therapy demonstrated efficacious outcomes and manageable safety among patients with high-tumor burden FL.

At the 65th ASH Annual Meeting,...

01/12/2024

Oncology

Conference Coverage

Exploring Possibilities for the Future of Chronic Lymphocytic Leukemia Treatment

01/12/2024

Adrian Wiestner , MD;

At the 65th ASH Annual Meeting, Adrian Wiestner, MD, discusses exciting possibilities for the future of chronic lymphocytic leukemia treatment, including the prospect of time-limited treatment periods and T-cell-engaging bispecific antibodies.

At the 65th ASH Annual Meeting,...

01/12/2024

Oncology

Jeffrey Matous, MD, Sarah Cannon Research Institute

Conference Coverage

Talquetamab Plus Pomalidomide Shows Promising Efficacy, Manageable Safety for Patients With MM

01/11/2024

Jeffrey Matous , MD;

At the 65th ASH Annual Meeting, Jeffrey Matous, MD, shared initial trial results that talquetamab plus pomalidomide demonstrated rapid, deep responses among patients with R/R multiple myeloma and ≥2 prior lines of therapy.

At the 65th ASH Annual Meeting,...

01/11/2024

Oncology

Alina Markova, MD, Memorial Sloan Kettering

Conference Coverage

Topical Ruxolitinib Shows Promise for Treatment of Patients With Chronic Cutaneous GVHD

01/11/2024

Alina Markova , MD;

At the 65th ASH Annual Meeting in San Diego, California, Alina Markova, MD, shared study results that demonstrated ruxolitinib 1.5% cream was safe and effective compared to placebo in treating cutaneous nonsclerotic and superficially...

At the 65th ASH Annual Meeting...

01/11/2024

Oncology

Conference Coverage

Updated Findings on Efficacy and Safety of Tazemetostat Plus Lenalidomide and Rituximab for Patients With R/R FL

01/10/2024

David J. Andorsky ;

At the 65th ASH Annual Meeting, David Andorsky, MD, discussed updated findings from the Symphony-1 trial after a 22.5-month follow-up.

At the 65th ASH Annual Meeting,...

01/10/2024

Oncology

Conference Coverage

Prognostic Value of Undetectable MRD Status Among Patients With Follicular Lymphoma Post-Initial Treatment

01/10/2024

Alexey Danilov , MD;

At the 65th ASH Annual Meeting, Alexey Danilov, MD, analyzes the prognostic value of undetectable MRD among patients with follicular lymphoma initially treated with chemotherapy.

At the 65th ASH Annual Meeting,...

01/10/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology